Cyclosporine-associated neurotoxicity. The need for a better guide for immunosuppressive therapy.

Heart transplantation has become the most effective treatment of end-stage heart failure in selected patients. More than 30 000 heart transplantations have been performed worldwide since its introduction in 1967, with a current 1-year survival rate of 85% and 5-year survival rate of 70%.1 Besides the enormous survival advantage associated with heart transplantation compared with all other therapies, it also usually is associated with the restoration of a nearly normal age-predicted functional capacity.